Clinical trials: sponsored by EMD Serono Research & Development Institute, Inc.
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
- Trial name
- NCT02625623
- Testing
- Avelumab, Irinotecan, Paclitaxel
- Where
- 75 sites in United States, Australia and 8 more
- Volunteers
- 371 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Ovarian Cancer
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
- Trial name
- NCT03704467
- Testing
- M6620, Avelumab, Carboplatin
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
The goal of this study was to evaluate the safety, tolerability and effectiveness of oral cladribine when taken in combination with Interferon-beta (IFN-beta) therapy for the treatment of multiple sclerosis (MS).
- Trial name
- ONWARD (NCT00436826)
- Testing
- Cladribine, Interferon-beta (IFN-beta)
- Where
- 39 sites in United States, Italy and 2 more
- Volunteers
- 172 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Rheumatoid Arthritis
Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis
The purpose of this study was to determine the efficacy, dose response, and safety of M52951 in participants with Rheumatoid Arthritis (RA), and to consider a dose to took forward into Phase III development.
- Trial name
- NCT03233230
- Testing
- M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID
- Where
- 97 sites in United States, Argentina and 10 more
- Volunteers
- 390 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Small Cell Lung Cancer
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
M3814 is an investigational drug under evaluation for treatment of lung cancer. The purpose of the study was to assess the Safety and Efficacy of M3814 in combination with chemotherapy with SCLC ED.
- Trial name
- NCT03116971
- Testing
- M3814, Cisplatin, Etoposide
- Where
- 80 sites in United States, Belgium and 11 more
- Volunteers
- 2 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Carcinoma, Non-Small-Cell Lung
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
The main purpose of this study was to demonstrate superiority with regard to overall survival of avelumab versus docetaxel in participants with programmed death ligand 1 (PD-L1) positive, non-small cell lung cancer (NSCLC) after…
- Trial name
- NCT02395172
- Testing
- Avelumab, Docetaxel
- Where
- 260 sites in United States, Argentina and 27 more
- Volunteers
- 792 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Osteoarthritis, Knee
A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial of Sprifermin administered intra-articularly in participants with primary osteoarthritis of the knee and Kellgren-Lawrence Grade 2…
- Trial name
- FORWARD (NCT01919164)
- Testing
- Sprifermin
- Where
- 13 sites in United States, Argentina and 6 more
- Volunteers
- 549 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Advanced Solid Tumor
M6620 First in Human Study
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
- Trial name
- NCT02157792
- Testing
- M6620, Gemcitabine, Cisplatin
- Where
- 31 sites in United States, United Kingdom
- Volunteers
- 200 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic or Locally Advanced Unresectable Solid Tumors
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
This is a Phase I, open-label study to determine the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and preliminary antitumor activity of MS201408-0005A as single agent (Part IA only) and in combination with…
- Trial name
- NCT03306420
- Testing
- M4112
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Advanced Solid Tumor
First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
The purpose of this study was to evaluate the safety and tolerability of VX-984 (M9831) administered alone and in combination with pegylated liposomal doxorubicin (PLD), and to determine the maximum tolerated dose (MTD) and…
- Trial name
- NCT02644278
- Testing
- VX-984 120 mg + PLD 40 mg/m^2, VX-984 240 mg + PLD 40 mg/m^2, VX-984 480 mg + PLD 40 mg/m^2
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Systemic Sclerosis-associated Interstitial Lung Disease
Abituzumab in SSc-ILD
The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the…
- Trial name
- NCT02745145
- Testing
- Abituzumab 1500 mg, Abituzumab 500 mg
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 24 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing-Remitting Multiple Sclerosis
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade of lymphopenia, Cluster of…
- Trial name
- NCT03284970
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Rheumatoid Arthritis
Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently…
- Trial name
- NCT02784106
- Testing
- M2951
- Where
- 2 sites in United States, Germany
- Volunteers
- 65 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lupus Erythematosus, Systemic
MSC2364447C Phase 1b in Systemic Lupus Erythematosus
The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic…
- Trial name
- NCT02537028
- Testing
- MSC2364447C
- Where
- 13 sites in United States, Bulgaria
- Volunteers
- 24 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.